Compositions and methods for treating mucositis
US-2024415798-A1 · Dec 19, 2024 · US
Methods and compositions for treating ineffective erythropoiesis
US2017327800A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2017327800-A1 |
| Application number | US-201715663361-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jul 28, 2017 |
| Priority date | Oct 17, 2011 |
| Publication date | Nov 16, 2017 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
First claim
Opening claim text (preview).
1 . A method for treating anemia with ringed sideroblasts in a patient, the method comprising administering to a patient in need thereof a polypeptide comprising an amino acid sequence that is at least 90% identical to the sequence of amino acids 29-109 of SEQ ID NO: 1, wherein the polypeptide comprises an acidic amino acid at the position corresponding to position 79 of SEQ ID NO: 1. 2 - 10 . (canceled) 11 . The method of claim 1 , wherein the polypeptide comprises an amino acid sequence that is at least 95% identical to the sequence of amino acids 29-109 of SEQ ID NO: 1. 12 . The method of claim 1 , wherein the polypeptide comprises an amino acid sequence that is at least 98% identical to the sequence of amino acids 29-109 of SEQ ID NO: 1. 13 . The method of claim 1 , wherein the polypeptide comprises an amino acid sequence that is identical to the sequence of amino acids 29-109 of SEQ ID NO: 1. 14 - 18 . (canceled) 19 . The method of claim 1 , wherein the polypeptide comprises an amino acid sequence that is at least 90% identical to the sequence of amino acids 25-131 of SEQ ID NO: 1. 20 . The method of claim 1 , wherein the polypeptide comprises an amino acid sequence that is at least 95% identical to the sequence of amino acids 25-131 of SEQ ID NO: 1. 21 . The method of claim 1 , wherein the polypeptide comprises the sequence of amino acids 25-131 of SEQ ID NO: 1. 22 . The method of claim 1 , wherein the polypeptide comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 28. 23 . The method of claim 1 , wherein the polypeptide comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 28. 24 . The method of claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 28. 25 . The method of claim 1 , wherein the polypeptide binds to GDF11. 26 . The method of claim 1 , wherein the polypeptide binds to GDF8. 27 . The method of claim 1 , wherein the polypeptide binds to GDF11 and GDF8. 28 . The method of claim 1 , wherein the acidic amino acid is aspartic acid (D). 29 . The method of claim 1 , wherein the acidic amino acid is glutamic acid (E). 30 . The method of claim 1 , wherein the patient is refractory to erythropoietin treatment. 31 . The method of claim 1 , wherein the patient has elevated levels of erythropoietin. 32 . The method of claim 1 , wherein the patient has myelodysplastic syndrome. 33 . The method of claim 1 , wherein the patient has refractory anemia with ringed sideroblasts. 34 . The method of claim 24 , wherein the patient has myelodysplastic syndrome. 35 . The method of claim 24 , wherein the patient has refractory anemia with ringed sideroblasts. 36 . The method of claim 1 , wherein the polypeptide is administered subcutaneously.
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2017327800A1 cover?
- In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
- Who is the assignee on this patent?
- Acceleron Pharma Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K38/18. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Nov 16 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).